Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer
International Journal of Clinical Oncology · 2026
DOI: 10.1007/s10147-026-03102-2 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Neal Shore und 8 weiteren Autor:innen. Beteiligte Einrichtung: START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Taxoids, Bridged-Ring Compounds, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Background
Metastatic castration-resistant prostate cancer (mCRPC) treatment commonly includes first-line (1L) androgen receptor pathway inhibitors (ARPIs) followed by second-line (2L) taxane-based chemotherapy. Adverse events (AEs) may lead to early taxane discontinuation, which can negatively affect outcomes and costs. This retrospective observational study assessed real-world outcomes, AEs, and costs of 2L taxane therapy by number of cycles among patients with mCRPC previously treated with a 1L ARPI; outcomes were compared with patients receiving 2L ARPI.
Methods
Overall survival (OS; overall and by number of taxane cycles received) was determined for 2L taxane and compared with 2L ARPI using the Flatiron Health electronic health record database (Jul 1, 2012, to Jun 30, 2020). Taxane-related AEs and associated costs were estimated using the IQVIA PharMetrics® Plus claims database (Jan 1, 2013, to Aug 31, 2021).
Results
Overall, 2L ARPI ( n = 473) vs. taxane ( n = 214) was associated with longer median OS (15.4 vs. 13.6 months). Patients receiving > 8 ( n = 48) vs. ≤ 8 taxane cycles ( n = 166) had longer median OS (18.4 vs. 11.9 months; p = 0.006). Patients receiving > 8 vs. ≤ 8 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).
Conclusion
Patients who received > 8 cycles of 2L taxane had longer observed survival. However, these results are subject to selection bias and immortal time bias. Prospective or time-adjusted analyses are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- Asclepius Analytics, New York, NY, USA.
- IQVIA, Wayne, PA, USA.
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Shore, N., Nguyen, J., Kang, B., Sawhney, A., Byrne, C., Tang, J., Gorritz, M., Chen, C. C., & Patel, J. (2026). Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03102-2
Vancouver
Shore N, Nguyen J, Kang B, Sawhney A, Byrne C, Tang J, et al. Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03102-2
BibTeX
@article{Shore2026,
author = {Shore, Neal and Nguyen, Jennifer and Kang, Barinder and Sawhney, Amrita and Byrne, Clare and Tang, Jackson and Gorritz, Magdaliz and Chen, Chi-Chang and Patel, Jeetvan},
title = {Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer},
journal = {International Journal of Clinical Oncology},
year = {2026},
doi = {10.1007/s10147-026-03102-2}
}
EUVIMED